Perfusion based microfluidic system for pharmacological profiling of neuronal networks by MacKerron, C. et al.
MacKerron, C. and Robertson, G. and Bushell, T.J. and Zagnoni, M. 
(2016) Perfusion based microfluidic system for pharmacological 
profiling of neuronal networks. In: 20th International Conference on 
Miniaturized Systems for Chemistry and Life Sciences (MicroTAS 2016). 
Chemical and Biological Microsystems Society, San Diego, CA, pp. 445-
446. ISBN 9781510834163 , 
This version is available at https://strathprints.strath.ac.uk/60310/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
PERFUSION BASED MICROFLUIDIC SYSTEM FOR 
PHARMACOLOGICAL PROFILING OF NEURONAL NETWORKS 
C. MacKerron1, G. Robertson1, T.J. Bushell2 and M. Zagnoni1 
1Department of Electronic and Electrical Engineering, University of Strathclyde, UK 
2Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, UK 
 
ABSTRACT 
This work presents the integration of a semi-automated microfluidic platform that utilizes calcium 
imaging to enable the pharmacological characterization of functionally connected, but 
environmentally isolated neuronal networks. This approach allows, for the first time, to assess the 
cause-effect relationship of neuronal communication following drug application, thus allowing the 
pharmacological characterisation of novel drugs proposed to influence communication between 
neuronal networks. 
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INTRODUCTION 
Many in vitro systems fail to recreate the biological complexity of the in vivo neural 
microenvironment, which reduces the likelihood of drugs that depend on in vitro assays being 
effective during clinical trials [1]. Having previously demonstrated functional synaptic 
communication between independent neural networks in a microfluidic format [2], we have now 
integrated computer controlled fluid perfusion into the system for CNS drug discovery. The platform 
enables user-defined delivery of up to four different perfusates and simultaneous recordings of 
cellular activity via calcium imaging, from both the direct, and indirectly chemically stimulated 
neuronal co-cultures. 
 
EXPERIMENTAL 
Two layer microfluidic devices were fabricated using standard soft lithography procedures with 
PDMS devices bonded to glass coverslips, followed by UV sterilization and poly-l-lysine (10ߤg ml-1) 
treatment. Mixed primary hippocampal cells were cultured in the microfluidic devices within two 
environmentally separated chambers that allowed synaptic connections to be formed with each other 
via an array of microchannels [3] (figure 1). The perfusion of multiple compounds in one chamber 
(direct stimulation) was achieved using computer controlled syringe driven perfusion pumps which 
were connected to the inlets/outlets of the microfluidic device on the day of experimentation. 
Live/dead assays were performed on microfluidic cultures following perfusion across a range of flow 
rates with cell death determined using live/dead staining with hoechst and propidium iodide. 
Characterisation of perfusion in the microfluidic device was performed using calcein (50ߤM), and the 
pharmacological profiling of glutamate activity achieved using a range of glutamate concentrations 
and a combination of ionotropic antagonists.  
Figure 1:  Dual chamber microfluidic device, modified with inlets and outlets for  the semi-automated  
perfusion and withdrawal of fluid 
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RESULTS AND DISCUSSION 
Perfusion of calcein across multiple recordings revealed consistent wash on/off fluorescent 
profiles in the absence of fluid cross contamination between perfused and non-perfused chambers. 
This indicates that any changes to indirect neuronal activity is a consequence of functional synaptic 
communication between the two neuronal networks. A flow rate of 4ߤl min-1 preserved cell health in 
both exposed and naïve neural networks following live/dead assays, and a glutamate concentration 
response curve following direct stimulation revealed an EC50 of 4ߤM. Pharmacological manipulation 
of neuronal activity was also achieved as the neuronal response to glutamate (3ߤM) was reversibly 
reduced in the presence of glutamate antagonists (NBQX/DL-AP5/MCPG 20/100/500ߤM; Figure 2). 
This demonstrates, as a proof of principle, that this system is capable of carrying out pharmacological 
profiling of novel drugs.  
 
Figure 2: Reversible inhibition of neuronal activity in response to glutamate perfusion 
 
CONCLUSION 
Mapping the direct/indirect neuronal network response to drug application will allow a better  
understanding of the pharmacological profile of new drugs and how they influence the  
communication between neuronal networks. The novel microfluidic platform presented here produces 
high-throughput pharmacological data for agonist/antagonist compounds in a neurological setting and 
has the potential to be used for investigating the therapeutic potential of novel compounds for CNS 
disorders. 
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